ImmunityBio Inc (NASDAQ: IBRX) has seen a decline in its stock price by -14.64 in relation to its previous close of 9.15. However, the company has experienced a -13.13% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-05-06 that You’ll get no argument from me that GameStop (NYSE: GME ) is one of the best meme stocks to sell. However, the video game retailer has been around a long time, suggesting it’s not the worst of the meme stocks to sell.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
The stock has a 36-month beta value of 0.97. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IBRX is 137.56M, and at present, short sellers hold a 39.87% of that float. On May 07, 2024, the average trading volume of IBRX was 6.99M shares.
IBRX’s Market Performance
The stock of ImmunityBio Inc (IBRX) has seen a -13.13% decrease in the past week, with a 36.78% rise in the past month, and a 93.32% gain in the past quarter. The volatility ratio for the week is 17.72%, and the volatility levels for the past 30 days are at 16.48% for IBRX. The simple moving average for the last 20 days is 23.59% for IBRX stock, with a simple moving average of 116.61% for the last 200 days.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Neutral.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $4 based on the research report published on May 12, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $8. The rating they have provided for IBRX stocks is “Buy” according to the report published on August 03rd, 2022.
IBRX Trading at 38.78% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.83% of loss for the given period.
Volatility was left at 16.48%, however, over the last 30 days, the volatility rate increased by 17.72%, as shares surge +26.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +123.14% upper at present.
During the last 5 trading sessions, IBRX fell by -13.13%, which changed the moving average for the period of 200-days by +170.24% in comparison to the 20-day moving average, which settled at $6.40. In addition, ImmunityBio Inc saw 55.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBRX starting from BLASZYK MICHAEL D, who purchase 71,915 shares at the price of $2.75 back on Jun 05 ’23. After this action, BLASZYK MICHAEL D now owns 71,915 shares of ImmunityBio Inc, valued at $198,023 using the latest closing price.
Brennan John Owen, the Director of ImmunityBio Inc, purchase 25,000 shares at $2.83 during a trade that took place back on Jun 02 ’23, which means that Brennan John Owen is holding 25,000 shares at $70,700 based on the most recent closing price.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -580.97 for the present operating margin
- -33.96 for the gross margin
The net margin for ImmunityBio Inc stands at -993.59. The total capital return value is set at -0.81.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated 3.29 points at debt to capital in total, while cash flow to debt ratio is standing at -0.43. The debt to equity ratio resting at -1.44. The interest coverage ratio of the stock is -6.11.
Currently, EBITDA for the company is -342.85 million with net debt to EBITDA at -1.71. When we switch over and look at the enterprise to sales, we see a ratio of 9494.98. The receivables turnover for the company is 0.2for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.05.
Conclusion
To sum up, ImmunityBio Inc (IBRX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
